Published in Am Heart J on October 01, 2004
Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation (2010) 2.89
A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39
Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ (2005) 2.23
Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J (2008) 1.70
Emergency department and office-based evaluation of patients with chest pain. Mayo Clin Proc (2010) 1.44
ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing. PLoS One (2011) 1.21
Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol (2010) 1.08
Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol (2011) 1.00
The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk Manag (2010) 0.97
MicroRNAs as biomarkers for myocardial infarction. Curr Atheroscler Rep (2012) 0.94
Combined determination of highly sensitive troponin T and copeptin for early exclusion of acute myocardial infarction: first experience in an emergency department of a general hospital. Vasc Health Risk Manag (2011) 0.89
Rapid and sensitive detection of troponin I in human whole blood samples by using silver nanoparticle films and microwave heating. Clin Chem (2011) 0.89
Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. Clin J Am Soc Nephrol (2012) 0.88
A review of troponins in ischemic heart disease and other conditions. Int J Angiol (2007) 0.84
Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review. Clin Biochem (2015) 0.79
Financial impact of a targeted reduction in cardiac enzyme testing at a community hospital. J Community Hosp Intern Med Perspect (2016) 0.78
Acute coronary syndromes: Troponin triumphant? Nat Rev Cardiol (2009) 0.75
Chemiluminometric Immunosensor for High-Sensitivity Cardiac Troponin I Employing a Polymerized Enzyme Conjugate as a Tracer. Sci Rep (2015) 0.75
Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med (2017) 0.75
Identification of myocardial injury in the emergency setting. Clin Biochem (2009) 0.75
Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction. J Am Heart Assoc (2017) 0.75
Biomarkers in acute coronary artery disease. Wien Med Wochenschr (2012) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J (2004) 3.45
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Visualisation and quantification of peri-operative myocardial infarction after coronary artery bypass surgery with contrast-enhanced magnetic resonance imaging. Eur Heart J (2004) 2.77
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation (2012) 2.74
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J (2016) 2.70
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation (2011) 2.61
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J (2009) 2.61
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J (2013) 2.52
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol (2003) 2.36
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace (2015) 2.35
The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart (2010) 2.24
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18
How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J (2012) 2.00
Management of grown up congenital heart disease. Eur Heart J (2003) 1.94
Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J (2010) 1.88
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83
Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med (2003) 1.81
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol (2003) 1.75
Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol (2009) 1.73
Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol (2009) 1.71
Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J (2008) 1.70
Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J (2006) 1.70
Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation (2004) 1.67
Improved clinical outcome after acute myocardial infarction in hospitals participating in a Swedish quality improvement initiative. Circ Cardiovasc Qual Outcomes (2009) 1.67
Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol (2013) 1.67
Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. Am Heart J (2006) 1.66
Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol (2007) 1.66
Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision-making. Clin Chem (2008) 1.62
Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Circulation (2007) 1.61
N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol (2002) 1.59
Clinical and analytical performance of the liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC-II substudy. Clin Chem (2003) 1.54
Small changes in troponin T levels are common in patients with non-ST-segment elevation myocardial infarction and are linked to higher mortality. J Am Coll Cardiol (2013) 1.53
Will the universal definition of myocardial infarction criteria result in an overdiagnosis of myocardial infarction? Am J Cardiol (2008) 1.51
A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation. Am Heart J (2002) 1.48
Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol (2010) 1.44
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. Eur Heart J (2007) 1.43
Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J (2011) 1.42
Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation (2007) 1.41
Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J (2009) 1.40
Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J (2007) 1.40
Use of 13 disease registries in 5 countries demonstrates the potential to use outcome data to improve health care's value. Health Aff (Millwood) (2011) 1.39
[Evaluation of patients with chest pain: Can we settle with measurement of troponin only on arrival?]. Lakartidningen (2014) 1.39
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace (2016) 1.39
Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease. Am J Med (2003) 1.38
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J (2004) 1.34
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J (2012) 1.29
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol (2004) 1.24
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost (2014) 1.22
Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J (2008) 1.21
Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol (2002) 1.15
Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation (2013) 1.10
Biomarkers in atrial fibrillation: a clinical review. Eur Heart J (2013) 1.07
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol (2006) 1.02
High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J (2013) 1.00
GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One (2013) 0.98
Clinical performance of two highly sensitive cardiac troponin I assays. Clin Chem (2008) 0.98
Thoughts, actions, and factors associated with prehospital delay in patients with acute coronary syndrome. Heart Lung (2007) 0.96
Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries. Eur Heart J Acute Cardiovasc Care (2013) 0.96
Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? Intern Emerg Med (2013) 0.96
Improving guideline adherence through intensive quality improvement and the use of a National Quality Register in Sweden for acute myocardial infarction. Qual Manag Health Care (2007) 0.96
Factors that influence the use of ambulance in acute coronary syndrome. Am Heart J (2008) 0.96
Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet (2009) 0.95
Natriuretic peptides in unstable coronary artery disease. Eur Heart J (2004) 0.93
A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. Int J Cardiol (2004) 0.93
High-sensitive cardiac troponin T outperforms novel diagnostic biomarkers in patients with acute chest pain. Clin Chim Acta (2012) 0.92
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J (2003) 0.92
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol (2006) 0.92
Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. Am Heart J (2004) 0.91
From European to national guidelines on heart disease. Scand Cardiovasc J (2010) 0.91
The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J (2002) 0.89
Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost (2014) 0.87
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol (2005) 0.87
How to use C-reactive protein in acute coronary care. Eur Heart J (2013) 0.86
Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. Am Heart J (2010) 0.86
Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients. Int J Cardiol (2006) 0.86
Acute coronary syndrome - the present and future role of biomarkers. Clin Chem Lab Med (2013) 0.85
Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction. Eur Heart J (2004) 0.85
Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin Biochem (2009) 0.84
Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and related to cardiovascular dysfunction. Clin Chem (2012) 0.84
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol (2013) 0.84